BMT Tandem "Scientific" Meeting
Ballroom E-H (Salt Palace Convention Center)
Chairs:
Christopher G. Kanakry, MD
and
Edwin M. Horwitz, MD, PhD
Summary:
Abstracts: #2668, 2567, 2678, 2415, 2719, 2652, 1830, 2723
Ex Vivo Treatment of Umbilical Cord Blood with Prostaglandin E2 Alters the Molecular and Functional Properties of T Cells Via Modulating Wnt/β-Catenin Signaling
Lequn Li, MD, PhD, Beth Israel Deaconess Medical Center, Harvard Medical School;
Anoma Nellore, MD, Beth Israel Deaconess Medical Center, Harvard Medical School;
Sean M McDonough, MS, Dana-Farber Cancer Institute;
Ioannis Politikos, MD, Beth Israel Deaconess Medical Center, Harvard Medical School;
Haesook Kim, PhD, Dana-Farber Cancer Institute;
Sarah Nikiforow, MD PhD, Dana-Farber Cancer Institute;
Robert J. Soiffer, MD, Dana-Farber Cancer Institute;
Joseph H Antin, MD, Dana-Farber Cancer Institute;
Karen Ballen, MD, Massachusetts General Hospital;
Corey Cutler, MD MPH FRCP(C), Dana-Farber Cancer Institute;
Jerome Ritz, MD, Dana-Farber Cancer Institute;
Vassiliki A Boussiotis, MD PhD, Beth Israel Deaconess Medical Center, Harvard Medical School
Impaired B Cell Clonotype Diversification After Allogeneic Hematopoietic Cell Transplantation Predicts Graft-Versus-Host Disease
Aaron Logan, MD, PhD, Stanford University School of Medicine;
Bita Sahaf, PhD, Stanford University School of Medicine;
Bing Zhang, MD, Stanford University School of Medicine;
Sally Arai, MD, Stanford University School of Medicine;
Victoria Carlton, PhD, Sequenta, Inc.;
Jianbiao Zheng, PhD, Sequenta, Inc.;
Martin Moorhead, PhD, Sequenta, Inc.;
Mark R. Krampf, Stanford University School of Medicine;
Carol D. Jones, Stanford University School of Medicine;
Amna N. Waqar, Stanford University School of Medicine;
Malek Faham, MD, PhD, Sequenta, Inc.;
Judith A. Shizuru, MD, PhD, Stanford University School of Medicine;
James L. Zehnder, MD, Stanford University School of Medicine;
David B. Miklos, MD, PhD, Stanford University School of Medicine
Markers of Angiogenesis and Neovascularization Correlate with Functional Recovery of Thymic Epithelial Cells and T Cell Immune Reconstitution After Cord Blood Transplantation in Adults
Ioannis Politikos, MD, Beth Israel Deaconess Medical Center, Harvard Medical School;
Haesook Kim, PhD, Dana-Farber Cancer Institute;
Julia Brown, PhD, Beth Israel Deaconess Medical Center, Harvard Medical School;
Sean M McDonough, MS, Dana-Farber Cancer Institute;
Lequn Li, MD, PhD, Beth Israel Deaconess Medical Center, Harvard Medical School;
Corey Cutler, MD MPH FRCP(C), Dana-Farber Cancer Institute;
Robert J. Soiffer, MD, Dana-Farber Cancer Institute;
Joseph H Antin, MD, Dana-Farber Cancer Institute;
Karen Ballen, MD, Massachusetts General Hospital;
Jerome Ritz, MD, Dana-Farber Cancer Institute;
Vassiliki A Boussiotis, MD PhD, Beth Israel Deaconess Medical Center, Harvard Medical School
Stem-Like Characteristics in a Subset of CD161 Expressing Human Memory CD4+ T Cells Facilitates Their Survival After Chemotherapy
Abdullah Alsuliman, Imperial College;
Ahmad Khoder, Imperial College;
Kate Stringaris, Imperial College;
Takuya Sekine, Imperial College;
Bonnie Razzaghi, Imperial College;
Hugues de Lavallade, Imperial College;
Anushruthi Sarvaria, Imperial College;
David Marin, Imperial College;
Katayoun Rezvani, MD; PhD, MD Anderson Cancer Center
Autologous aGVHD Associated with Infusion of T-Cells with Engineered Specificity for NY-ESO-1 and Lage-1 Following High-Dose Melphalan and ASCT in Patients with Multiple Myeloma
Alfred L Garfall, MD, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania;
Michael Kalos, PhD, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania;
Emma E. Furth, MD, Perelman School of Medicine, University of Pennsylvania;
Dan Vogl, MD, MSCE, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania;
Brendan Weiss, MD, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania;
Joshua Cantor, MD, Perelman School of Medicine, University of Pennsylvania;
Minnal Gupta, MS, Perelman School of Medicine, University of Pennsylvania;
Bruce Levine, PhD, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania;
Aaron Rapoport, MD, Greenebaum Cancer Center, University of Maryland;
Lilliam Ribeiro, MBe, Adaptimmune, LLC;
Bent Jakobsen, PhD, Adaptimmune, LLC;
Dominic Smethurst, MD, Adaptimmune, LLC;
Gwendolyn Binder-Scholl, PhD, Adaptimmune, LLC;
Carl H. June, MD, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania;
Edward A. Stadtmauer, MD, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania
Epitopes of CMVpp65 Co-Presented by Multiple Allelic Variants of HLA Class-I Antigens: Implications for Adoptive Immunotherapy for CMV Using Third Party Donor –Derived CMV Specific CTLs
Aisha Nasreen Hasan, MD, Memorial Sloan-Kettering Cancer Center;
Guenther Koehne, MD, PhD, Memorial Sloan-Kettering Cancer Center;
Annamalai Selvakumar, PhD, Sloan Kettering Inst Cancer Res;
Ekaterina S. Doubrovina, MD, PhD, Memorial Sloan-Kettering Cancer Center;
Susan Prockop, MD, Memorial Sloan-Kettering Cancer Center;
Richard O'Reilly, MD, Memorial Sloan-Kettering Cancer Center
Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Mesenchymal Stromal Cells: A Prospective, Multicentric, Phase 1 Study
Giovanna Lucchini, HSCT pediatric unit, and Laboratory of Cell Therapy “S. Verri”, San Gerardo Hospital;
Martino Introna, USC Hematology and Laboratory of Cell Therapy “G. Lanzani”, Ospedali Riuniti, Bergamo (Italy);
Erica Dander, M.Tettamanti Research Center;
Attilio Rovelli, HSCT pediatric unit, and Laboratory of Cell Therapy “S. Verri”, San Gerardo Hospital, Monza (Italy);
Adriana Balduzzi, HSCT pediatric unit, and Laboratory of Cell Therapy “S. Verri”, San Gerardo Hospital, Monza (Italy);
Daniela Valentina Longoni, HSCT pediatric unit, and Laboratory of Cell Therapy “S. Verri”, San Gerardo Hospital, Monza (Italy);
Fabio Pavan, HSCT pediatric unit, and Laboratory of Cell Therapy “S. Verri”, San Gerardo Hospital, Monza (Italy);
Francesca Masciocchi, HSCT pediatric unit, and Laboratory of Cell Therapy “S. Verri”, San Gerardo Hospital, Monza (Italy);
Alessandra Algarotti, USC Hematology and Laboratory of Cell Therapy “G. Lanzani”, Ospedali Riuniti, Bergamo (Italy);
Maria Caterina Mico, USC Hematology and Laboratory of Cell Therapy “G. Lanzani”, Ospedali Riuniti, Bergamo (Italy);
Anna Grassi, USC Hematology and Laboratory of Cell Therapy “G. Lanzani”, Ospedali Riuniti, Bergamo (Italy);
Sara Deola, HSCT unit, Bolzano (Italy);
Giuseppe Gaipa, HSCT pediatric unit, and Laboratory of Cell Therapy “S. Verri”, San Gerardo Hospital, Monza (Italy);
Daniela Belotti, HSCT pediatric unit, and Laboratory of Cell Therapy “S. Verri”, San Gerardo Hospital, Monza (Italy);
Paolo Perseghin, HSCT pediatric unit, and Laboratory of Cell Therapy “S. Verri”, San Gerardo Hospital, Monza (Italy);
Matteo Parma, HSCT adult unit, San Gerardo Hospital Monza;
Enrico Pogliani, HSCT adult unit, San Gerardo Hospital Monza;
Jose Golay, USC Hematology and Laboratory of Cell Therapy “G. Lanzani”, Ospedali Riuniti, Bergamo (Italy);
Chiara Capelli, USC Hematology and Laboratory of Cell Therapy “G. Lanzani”, Ospedali Riuniti, Bergamo (Italy);
Sara Cortellazzo, “M.Tettamanti” Research Centre, Monza (Italy);
Giovanna D`Amico, “M.Tettamanti” Research Centre, Monza (Italy);
Andrea Biondi, HSCT pediatric unit, and Laboratory of Cell Therapy “S. Verri”, San Gerardo Hospital, Monza (Italy);
Alessandro Rambaldi, USC Hematology and Laboratory of Cell Therapy “G. Lanzani”, Ospedali Riuniti, Bergamo (Italy);
Ettore Biagi, HSCT pediatric unit, and Laboratory of Cell Therapy “S. Verri”, San Gerardo Hospital, Monza (Italy)
CD25+ Regulatory T CELL-Depleted DONOR Lymphocyte Infusion for Relapse After Allogeneic Transplantation – A PHASE 1 Study
Sarah Nikiforow, MD PhD, Harvard Medical School;
Haesook Kim, PhD, Dana-Farber Cancer Institute;
Grace Kao, MD, Dana-Farber Cancer Institute;
Marie-Michele Sainvil, Dana-Farber Cancer Institute;
Sean M McDonough, MS, Dana-Farber Cancer Institute;
Philippe Armand, MD, PhD, Harvard Medical School;
Vincent T. Ho, MD, Harvard Medical School;
Edwin P. Alyea III, MD, Harvard Medical School;
Corey Cutler, MD MPH FRCP(C), Harvard Medical School;
Jerome Ritz, MD, Dana-Farber Cancer Institute;
Joseph H Antin, MD, Dana-Farber Cancer Institute;
Robert J. Soiffer, MD, Harvard Medical School;
John Koreth, MBBS, DPhil, Harvard Medical School
![[Visit Client Website]](images/banner.gif)